Dany Habr

3.9k total citations · 1 hit paper
86 papers, 2.9k citations indexed

About

Dany Habr is a scholar working on Genetics, Hematology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Dany Habr has authored 86 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Genetics, 69 papers in Hematology and 10 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Dany Habr's work include Hemoglobinopathies and Related Disorders (69 papers), Iron Metabolism and Disorders (49 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (20 papers). Dany Habr is often cited by papers focused on Hemoglobinopathies and Related Disorders (69 papers), Iron Metabolism and Disorders (49 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (20 papers). Dany Habr collaborates with scholars based in United States, Switzerland and Italy. Dany Habr's co-authors include Alì Taher, John B. Porter, Amal El‐Beshlawy, Mohsen Saleh Elalfy, Maria Domenica Cappellini, Vip Viprakasit, Antonis Kattamis, Bernard Roubert, Gabor Domokos and Yeşim Aydınok and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Dany Habr

85 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera

2015 594 citations Alessandro M. Vannucchi, Jean‐Jacques Kiladjian et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Dany Habr

Since Specialization

Citations

This map shows the geographic impact of Dany Habr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dany Habr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dany Habr more than expected).

Fields of papers citing papers by Dany Habr

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dany Habr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dany Habr. The network helps show where Dany Habr may publish in the future.

Co-authorship network of co-authors of Dany Habr

This figure shows the co-authorship network connecting the top 25 collaborators of Dany Habr. A scholar is included among the top collaborators of Dany Habr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dany Habr. Dany Habr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Evaluation of ChatGPT as a Reliable Source of Medical Information on Prostate Cancer for Patients: Global Comparative Survey of Medical Oncologists and Urologists 2024 ·Urology Practice ·Arnulf Stenzl, Andrew J. Armstrong, Eamonn Rogers, Dany Habr, Jochen Walz, Martin Gleave, Andrea Sboner, (unknown), Lucile Serfass, (unknown), (unknown), (unknown), (unknown), Cora N. Sternberg	0
2	Patients at the Heart of the Scientific Dialogue: An Industry Perspective 2023 ·Oncology and Therapy ·Dany Habr, (unknown), (unknown), (unknown)	3
3	Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy 2017 ·Leukemia Research ·Srđan Verstovšek, Claire Harrison, Jean‐Jacques Kiladjian, Carole B. Miller, Ahmad Naim, Dilan Paranagama, Dany Habr, Alessandro M. Vannucchi	22
4	Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera breakdown → 2015 ·New England Journal of Medicine ·Alessandro M. Vannucchi, Jean‐Jacques Kiladjian, Martin Grießhammer, Tamás Masszi, Simon Durrant, Francesco Passamonti, Claire Harrison, Fabrizio Pane, Pierre Zachée, Ruben A. Mesa, Shui He, Mark M. Jones, William M. Garrett, Jingjin Li, Ulrich Pirron, Dany Habr, Srđan Verstovšek	594
5	A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA) 2014 ·Blood ·Dudley J. Pennell, John B. Porter, Antonio Piga, Yongrong Lai, Amal El‐Beshlawy, Khawla Belhoul, Mohsen Saleh Elalfy, Akif Yeşilipek, Yurdanur Kılınç, Tomasz Lawniczek, Dany Habr, (unknown), Yiyun Zhang, Yeşim Aydınok	95
6	Deferasirox demonstrates a dose‐dependent reduction in liver iron concentration and consistent efficacy across subgroups of non‐transfusion‐dependent thalassemia patients 2013 ·American Journal of Hematology ·Alì Taher, John B. Porter, Vip Viprakasit, Antonis Kattamis, Suporn Chuncharunee, Pranee Sutcharitchan, Noppadol Siritanaratkul, Renzo Galanello, Zeynep Karakaş, Tomasz Lawniczek, Dany Habr, Jacqueline Ros, Yiyun Zhang, Maria Domenica Cappellini	15
7	Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study 2013 ·Annals of Hematology ·Alì Taher, John B. Porter, Vip Viprakasit, Antonis Kattamis, Suporn Chuncharunee, Pranee Sutcharitchan, Noppadol Siritanaratkul, Renzo Galanello, Zeynep Karakaş, Tomasz Lawniczek, Dany Habr, Jacqueline Ros, Zewen Zhu, Maria Domenica Cappellini	58
8	Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study 2012 ·Blood ·Alì Taher, John B. Porter, Vip Viprakasit, Antonis Kattamis, Suporn Chuncharunee, Pranee Sutcharitchan, Noppadol Siritanaratkul, Renzo Galanello, Zeynep Karakaş, Tomasz Lawniczek, Jacqueline Ros, Yiyun Zhang, Dany Habr, Maria Domenica Cappellini	109
9	Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes 2012 ·Haematologica ·(unknown), Carlo Finelli, Matteo Giovanni Della Porta, Pierre Fenaux, Michael Stadler, A. Guerci-Bresler, Mathias Schmid, K Taylor, (unknown), Dany Habr, (unknown), Bernard Roubert, Christian Rose	124
10	Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy 2012 ·Annals of Hematology ·John B. Porter, Mohsen Saleh Elalfy, Alì Taher, Yeşim Aydınok, L L Chan, (unknown), Pranee Sutcharitchan, Dany Habr, Nicolas Martin, Amal El‐Beshlawy	30
11	Reduction in liver iron concentration is consistent across subgroups of non-transfusion-dependent thalassemia patients treated with deferasirox : results from the 1-year thalassa study 2012 ·Alì Taher, John B. Porter, Vip Viprakasit, Antonis Kattamis, Suporn Chuncharunee, Pranee Sutcharitchan, Noppadol Siritanaratkul, R. Galanello, Zeynep Karakaş, Tomasz Lawniczek, Dany Habr, Jacqueline Ros, (unknown), (unknown)	2
12	Response of iron overload to deferasirox in rare transfusion‐dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias 2011 ·European Journal Of Haematology ·John B. Porter, Kai‐Hsin Lin, Photis Beris, Gian Luca Forni, Alì Taher, Dany Habr, Gabor Domokos, Bernard Roubert, Swee Lay Thein, (unknown)	24
13	A Randomized Phase II Study Evaluating the Efficacy and Safety of Deferasirox Versus Deferoxamine in Patients with Sickle Cell Disease (SCD): 2-Year Results Including Pharmacokinetics (PK) and Safety of Deferasirox with Concomitant Hydroxyurea Therapy 2011 ·Blood ·Elliott Vichinsky, Marcela Torres, Jonathan Glass, Caterina P. Minniti, Stéphane Barrette, Dany Habr, (unknown), Yiyun Zhang, Beatrice Files	3
14	Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β‐thalassaemia: results from the ESCALATOR study 2011 ·European Journal Of Haematology ·Alì Taher, Mohsen Saleh Elalfy, (unknown), Shahina Daar, Abdullah Al Jefri, Dany Habr, Ulrike Kriemler‐Krahn, Bernard Roubert, Amal El‐Beshlawy	9
15	EFFICACY OF DEFERASIROX IN PATIENTS WITH THALASSAEMIA MAJOR IS NOT AFFECTED BY A HISTORY OF HEPATITIS B OR C 2010 ·UCL Discovery (University College London) ·Cappellini, Mohsen Saleh Elalfy, Amal El‐Beshlawy, Antonis Kattamis, (unknown), (unknown), (unknown), Giovanni Quarta, Pranee Sutcharitchan, Alì Taher, Dany Habr, Bernard Roubert, John B. Porter	1
16	CONTINUED IMPROVEMENT IN CARDIAC T2WITH DEFERASIROX TREATMENT OVER 2 YEARS: RESULTS FROM THE EXTENSION OF EPIC CARDIAC SUBSTUDY IN BETA-THALASSAEMIA PATIENTS WITH MYOCARDIAL SIDEROSIS 2010 ·UCL Discovery (University College London)* ·Dudley J. Pennell, John B. Porter, Maria Domenica Cappellini, Ling Ling Chan, Amal El‐Beshlawy, Yeşim Aydınok, Hishamshah Mohd Ibrahim, Chi Kong Li, (unknown), Mohsen Saleh Elalfy, Antonios Kattamis, Geoffrey C.S. Smith, Dany Habr, Bernard Roubert, Alì Taher	2
17	Improved Treatment Satisfaction and Convenience with Deferasirox in Iron-Overloaded Patients with β-Thalassemia: Results from the ESCALATOR Trial 2010 ·Acta Haematologica ·Alì Taher, Abdullah Al Jefri, Mohsen Saleh Elalfy, (unknown), Shahina Daar, Diana Rofail, (unknown), Dany Habr, Ulrike Kriemler‐Krahn, Amal El‐Beshlawy	36
18	Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron‐overloaded patients with β‐thalassaemia: the ESCALATOR study 2009 ·European Journal Of Haematology ·Alì Taher, Amal El‐Beshlawy, Mohsen Saleh Elalfy, (unknown), Shahina Daar, Dany Habr, Ulrike Kriemler‐Krahn, Abdel Hmissi, Abdullah Al Jefri	126
19	Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias 2009 ·Haematologica ·Maria Domenica Cappellini, John B. Porter, Amal El‐Beshlawy, Chi Kong Li, (unknown), Mohsen Saleh Elalfy, Norbert Gattermann, Stéphane Giraudier, (unknown), L L Chan, Kai‐Hsin Lin, Christian Rosé, Alì Taher, SL Thein, Vip Viprakasit, Dany Habr, Gabor Domokos, Bernard Roubert, Antonis Kattamis, (unknown)	233
20	Reduction in labile plasma iron during treatment with deferasirox, a once‐daily oral iron chelator, in heavily iron‐overloaded patients with β‐thalassaemia 2008 ·European Journal Of Haematology ·Shahina Daar, Anil Pathare, Hanspeter Nick, Ulrike Kriemler‐Krahn, Abdel Hmissi, Dany Habr, Alì Taher	63

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact